Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two high-dose chemotherapy conditioning regimens before autologous stem cell transplantation in relapsed or refractory lymphoma
IRCT20200825048515N70Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of etoposide, cytarabine, melphalan, carboplatin and lomustine in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Transplant complications and Disease recurrence. Started Jul 2023; status: completed.
02
Drugs
etoposidecytarabinemelphalancarboplatinlomustine
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on IRCT20200825048515N70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N70.